Skip to content
DataLookout
Menu

NCT07123181

Oregano and Basil Leaves and Coronary Artery Disease

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 6 words
    • Primary completion pushed from Sep 28, 2026 to Dec 21, 2026
    • Study completion pushed from Oct 22, 2026 to Jan 30, 2027
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Notable Primary completion date: Mar 17, 2026 to Sep 28, 2026
    • Study completion date: Jun 2, 2026 to Oct 22, 2026
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Plasma inflammatory biomarkers
Timeframe: At the beginning of the study and two months later
Plasma lipids
Timeframe: At the beginning of the study and two months later

Secondary (3)

Plasma malondialdehyde
Urinary total polyphenols
Plasma PCSK9 and PAI-1 levels

Arms and interventions

ControlOther

Standard medical treatment

Higher polyphenol intake by consumption of oregano and basilExperimental

Daily consumption of oregano and basil leaves along with standard medical treatment

Other: Control (Standard treatment), Higher polyphenol intake by consumption of oregano and basil

Sites

1 site in 1 country

  • Imam Husain hospitalTehran, Tehran Province, Iran